Lipocine Price to Free Cash Flow Ratio 2012-2025 | LPCN

Lipocine price to free cash flow ratio from 2012 to 2025. Price to free cash flow ratio can be defined as

Lipocine Price to Free Cash Flow Ratio 2012-2025 | LPCN

Lipocine price to free cash flow ratio from 2012 to 2025. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.3B
Zoetis (ZTS)$67.2B
Daiichi Sankyo, - (DSNKY)$46.3B
Takeda Pharmaceutical (TAK)$45.6B
BeOne Medicines - (ONC)$33.5B
Sandoz Group AG (SDZNY)$26B
Summit Therapeutics (SMMT)$19.9B
Merck (MKKGY)$16.9B
Shionogi (SGIOY)$14.3B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.3B
Orion OYJ (ORINY)$11.4B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.7B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$7.2B
Ionis Pharmaceuticals (IONS)$6.6B
Madrigal Pharmaceuticals (MDGL)$6.5B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.2B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
ARS Pharmaceuticals (SPRY)$1.7B